HK Stock Market Move | AB&B BIO-TECH-B (02627) rose over 3%. The application for the listing of the quadrivalent influenza subunit vaccine has been approved by the National Medical Products Administration.

AB&B BIO-TECH-B (02627) rose more than 3%, reaching 2.71% as of the time of reporting, at 50.4 Hong Kong dollars, with a turnover of 5.0766 million Hong Kong dollars. On the news front, on September 3, AB&B BIO-TECH-B announced that the board of directors happily announced that the China National Medical Products Administration (NMPA) has approved the group's new drug application for a quadrivalent influenza virus subunit vaccine for the 6-35 month age group. As of the date of this announcement, this vaccine has become the first and only quadrivalent influenza virus subunit vaccine approved for market in China for all age groups. This product has undergone significant upgrades from traditional virus split vaccines, with advantages such as comprehensive protection, high component antigen purity, and low risk of adverse reactions.